NCT02803762View on ClinicalTrials.gov

Investigate Absorption, Metabolism, Excretion, and Mass Balance of Pacritinib

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions

Healthy

Interventions

DRUG

Pacritinib

400 mg \[14C\]pacritinib (containing 100 μCi radioactivity) administered orally as a single dose following at least a 10-hour fast (not including water) on Day 1

Trial Locations (1)

9713 GZ

QPS Netherlands B.V., Groningen